Email This Article

Headlines & Perspectives
Arena Defends Obesity Drug as Stock Plunges
By Adam Feuerstein
03/30/09 - 05:22 PM EDT
Arena Pharmaceuticals reported phase III trial data for obesity drug lorcaserin that did not hit all FDA standards.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,452.46 1,111.11 2,202.38 34.83
Oil *
78.82
UP
86.31
UP
11.19
UP
29.24
UP
1.03
10 Yr
3.48%
SPDR Gold
115.70
+0.83%
+1.02%
+1.35%
+3.05%
Data delayed 20 minutes

Brokerage Partners